ENVVENO MEDICAL CORP (NVNO) Fundamental Analysis & Valuation

NASDAQ:NVNO • US29415J2050

Current stock price

11.7 USD
+0.24 (+2.09%)
Last:

This NVNO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NVNO Profitability Analysis

1.1 Basic Checks

  • In the past year NVNO has reported negative net income.
  • In the past year NVNO has reported a negative cash flow from operations.
  • NVNO had negative earnings in each of the past 5 years.
  • In the past 5 years NVNO always reported negative operating cash flow.
NVNO Yearly Net Income VS EBIT VS OCF VS FCFNVNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M

1.2 Ratios

  • NVNO's Return On Assets of -65.87% is on the low side compared to the rest of the industry. NVNO is outperformed by 73.94% of its industry peers.
  • The Return On Equity of NVNO (-71.77%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.87%
ROE -71.77%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
NVNO Yearly ROA, ROE, ROICNVNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 1K -1K

1.3 Margins

  • NVNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVNO Yearly Profit, Operating, Gross MarginsNVNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. NVNO Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, NVNO has more shares outstanding
  • Compared to 5 years ago, NVNO has more shares outstanding
  • NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NVNO Yearly Shares OutstandingNVNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K
NVNO Yearly Total Debt VS Total AssetsNVNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -7.46, we must say that NVNO is in the distress zone and has some risk of bankruptcy.
  • NVNO has a worse Altman-Z score (-7.46) than 77.13% of its industry peers.
  • NVNO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.46
ROIC/WACCN/A
WACCN/A
NVNO Yearly LT Debt VS Equity VS FCFNVNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • NVNO has a Current Ratio of 13.58. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
  • NVNO has a better Current ratio (13.58) than 98.40% of its industry peers.
  • NVNO has a Quick Ratio of 13.58. This indicates that NVNO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NVNO (13.58) is better than 98.40% of its industry peers.
Industry RankSector Rank
Current Ratio 13.58
Quick Ratio 13.58
NVNO Yearly Current Assets VS Current LiabilitesNVNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. NVNO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 35.20% over the past year.
EPS 1Y (TTM)35.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, NVNO will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.76% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.52%
EPS Next 2Y40.61%
EPS Next 3Y25.63%
EPS Next 5Y18.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVNO Yearly Revenue VS EstimatesNVNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2026 2027 2028 5M 10M 15M 20M 25M
NVNO Yearly EPS VS EstimatesNVNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -100 -200 -300 -400

More info and screens

Find the best growth stocksShow best growing peers

1

4. NVNO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NVNO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVNO Price Earnings VS Forward Price EarningsNVNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVNO Per share dataNVNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 -40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as NVNO's earnings are expected to grow with 25.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.61%
EPS Next 3Y25.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NVNO Dividend Analysis

5.1 Amount

  • No dividends for NVNO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NVNO Fundamentals: All Metrics, Ratios and Statistics

ENVVENO MEDICAL CORP

NASDAQ:NVNO (4/17/2026, 8:00:02 PM)

11.7

+0.24 (+2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-27
Earnings (Next)04-28
Inst Owners20.99%
Inst Owner Change10.62%
Ins Owners11.45%
Ins Owner Change-4.45%
Market Cap7.72M
Revenue(TTM)N/A
Net Income(TTM)-19.47M
Analysts43.33
Price TargetN/A
Short Float %14.65%
Short Ratio4.12
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.28
P/tB 0.28
EV/EBITDA N/A
EPS(TTM)-44.45
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-25.57
FCFYN/A
OCF(TTM)-25.51
OCFYN/A
SpS0
BVpS41.11
TBVpS41.11
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -65.87%
ROE -71.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-55.71%
ROE(3y)-55.94%
ROE(5y)-67.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19.58%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.58
Quick Ratio 13.58
Altman-Z -7.46
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)30.57%
Cap/Depr(5y)103.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.38%
EPS Next Y97.52%
EPS Next 2Y40.61%
EPS Next 3Y25.63%
EPS Next 5Y18.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.71%
OCF growth 3YN/A
OCF growth 5YN/A

ENVVENO MEDICAL CORP / NVNO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ENVVENO MEDICAL CORP?

ChartMill assigns a fundamental rating of 2 / 10 to NVNO.


What is the valuation status for NVNO stock?

ChartMill assigns a valuation rating of 1 / 10 to ENVVENO MEDICAL CORP (NVNO). This can be considered as Overvalued.


Can you provide the profitability details for ENVVENO MEDICAL CORP?

ENVVENO MEDICAL CORP (NVNO) has a profitability rating of 0 / 10.